BIIB News Alert Biogen Idec Inc (BIIB) 305.56 11/18/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 9:38 PM

Biogen Idec Inc (BIIB) 305.56 $BIIB

Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:30PM CST
Kite Pharma (KITE) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for granting orphan medicinal product status to KTE-C19.
BIIB: 305.56 (+3.14), KITE: 41.77 (+1.47), ANIP: 55.66 (+2.79), AMAG: 35.34 (+0.58)

Actavis Strikes $66 Billion Deal for Botox Maker Allergan - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 18, 12:20PM CST
This acquisition will place Actavis among the top 10 pharma companies based on sales.
AGN: 213.37 (+4.17), BIIB: 305.56 (+3.14), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21)

Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:25AM CST
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 305.56 (+3.14), SNSS: 2.07 (-0.24), AMAG: 35.34 (+0.58), AFFX: 9.58 (+0.29)

Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
GlobeNewswire - Tue Nov 18, 7:41AM CST
Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera(R) in Germany. With this lawsuit Forward Pharma ("the Company"

does not seek to stop sales of Tecfidera(R) to MS patients, but rather seeks damages for what the Company believes are Biogen Idec's unlawful sales of Tecfidera(R) in Germany.
BIIB: 305.56 (+3.14), FWP: 21.14 (-0.58)

Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.94 (+0.32), DSX: 7.80 (-0.02), BIIB: 305.56 (+3.14), GE: 27.01 (+0.40), ALNY: 89.95 (+0.97), JCP: 7.32 (+0.06), MBLY: 47.33 (+0.35)

'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.94 (+0.32), DSX: 7.80 (-0.02), BIIB: 305.56 (+3.14), GE: 27.01 (+0.40), ALNY: 89.95 (+0.97), JCP: 7.32 (+0.06), MBLY: 47.33 (+0.35)

Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.42 (+0.51), BIIB: 305.56 (+3.14), GE: 27.01 (+0.40), NKE: 96.47 (+0.41), HAL: 48.54 (-0.69), TSN: 42.65 (-0.38), GSAT: 2.55 (-0.25), LULU: 44.80 (+0.38), AGN: 213.37 (+4.17), MACK: 8.94 (+0.32), WHR: 177.22 (+1.67), UA: 69.37 (+0.48), DSX: 7.80 (-0.02), ALNY: 89.95 (+0.97), MPC: 93.88 (+1.37), JCP: 7.32 (+0.06), SHW: 241.32 (+2.01), MBLY: 47.33 (+0.35), REGN: 413.22 (+13.57), BHI: 63.55 (-1.68)

Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 305.56 (+3.14), ALNY: 89.95 (+0.97), AMAG: 35.34 (+0.58), SNY: 48.36 (+0.82)

Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 29.54 (+0.83), MNK: 88.80 (+0.37), BIIB: 305.56 (+3.14), MYL: 56.24 (+1.11)

Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:20PM CST
Sanofi's (SNY) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of MS.
BIIB: 305.56 (+3.14), SNY: 48.36 (+0.82), NVS: 95.58 (+1.20)

Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 1:04PM CST
Puma Biotechnology, Inc.'s (PBYI) neratinib failed to show significant improvement in progression free survival (PFS) as a first-line treatment of HER2-positive breast cancer.
BIIB: 305.56 (+3.14), PFE: 30.59 (+0.27), PBYI: 223.00 (+11.45)

Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST

BIIB: 305.56 (+3.14), GILD: 103.71 (+3.27), INCY: 69.64 (-0.06), ALXN: 192.37 (+5.59), CELG: 106.78 (+2.42)

Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.56 (+3.14), KITE: 41.77 (+1.47), ANIP: 55.66 (+2.79), AMAG: 35.34 (+0.58)

Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.63 (+0.14), HAS: 56.12 (-0.25), BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), HAL: 48.54 (-0.69), M: 61.45 (-0.16), WMT: 83.79 (+0.22), SLB: 95.28 (-0.35), COG: 33.27 (-0.26), GILD: 103.71 (+3.27), EOG: 97.67 (+1.32), ALXN: 192.37 (+5.59), MRO: 32.06 (+0.24), CSCO: 26.59 (+0.12), BHI: 63.55 (-1.68)

Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 305.56 (+3.14), GERN: 3.17 (+0.19), ILMN: 189.85 (+6.94), AFFX: 9.58 (+0.29)

Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.56 (+3.14), ANIP: 55.66 (+2.79), AMAG: 35.34 (+0.58), AFFX: 9.58 (+0.29)

Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.56 (+3.14), JNJ: 108.83 (+0.53), GERN: 3.17 (+0.19), AFFX: 9.58 (+0.29)

Biogen Idec Falls 3.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.56 (+3.14)

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.95%
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.56 (+3.14)

Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 305.56 (+3.14), ISIS: 49.71 (+0.70), AZN: 73.98 (+1.48), SNY: 48.36 (+0.82)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Ping An's Bold Green Moves Ahead of APEC 2026

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...